Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the trial is to demonstrate evidence of clinical efficacy of HER-2 Protein AutoVac(TM)/QS-21, that is the number of evaluable patients with evidence of clinical benefit, defined as: • A complete response (CR) or partial response (PR), or • Stable disease (SD) for at least 6 months (26 weeks).
Critère d'inclusion
- Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion